A View from Emily Singer
Obama to Sign Stem Cells Order on Monday
The long-awaited reversal will lift federal funding restrictions on embryonic stem cell research.
President Obama has finally indicated that he will make good on his campaign promise to end federal funding restrictions on embryonic stem cell research. The restrictions, put in place by George W. Bush in 2001, specifically limited federal funding for embryonic stem-cell
research to a small number of cell lines already in existence, leaving
scientists who wanted to conduct cutting-edge research in this area
scrambling for private money.
According to an article from Reuters:
President Barack Obama, who opposes limits on federal funding of stem cell research, will sign an executive order related to the issue on Monday, an administration official said on Friday.
The official could not confirm the details of what Obama would sign, but advisers had previously said he favored lifting the eight-year limitation on funding of human embryonic stem cell research imposed by his predecessor, President George W. Bush.
The official also said Obama would make an announcement about a broader initiative to restore scientific integrity to government processes.
A piece I wrote in February on the expected reversal outlines the potential benefits for researchers:
Once the restriction is lifted, labs funded by federal dollars will be allowed to use most of the estimated 600 stem-cell lines that have been created around the globe. Researchers broadly agree that the newer lines, which were derived using more refined methods, are superior to the older ones. Using only the old lines is like “being required to use Microsoft Word 1998,” says Jeanne Loring, director of the Center for Regenerative Medicine at the Scripps Research Institute, in La Jolla, CA.
In addition, the earlier lines were derived using animal products, making them largely unfit for therapeutic use. “There are hundreds of embryonic stem-cell lines out there that have been made under the best conditions, and some of them are patient ready,” says John Gearhart, director of the Institute for Regenerative Medicine at the University of Pennsylvania, in Philadelphia. “They have greater utility, performance, and safety than [the Bush-approved] lines.”
Scientists will also be able to study cell lines that are genetically encoded for specific diseases–perhaps one of the most promising near-term uses of embryonic stem cells. (None of the Bush-approved lines have these qualities.) “One of the clear opportunities that has not been available are lines generated from embryos that carry mutations for Huntington’s disease, amyotrophic lateral sclerosis (ALS), and cystic fibrosis,” says Story Landis, director of the National Institute for Neurological Disorders and Stroke, in Bethesda, MD, and chair of the NIH’s Stem Cell Task Force. These cells provide unprecedented access to the molecular processes underlying disease; they can be prodded to develop into the cell type affected in a specific disease, such as motor neurons in ALS, so that scientists can watch the disease unfold at a cellular level. These cells can also be used to screen new drugs.
AI is here. Will you lead or follow?
Join us at EmTech Digital 2019.